IgGenix is a startup based in the United States, most recent round Series-c-plus, 1 tracked investor.
Based in the United States, IgGenix is a startup. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
IgGenix is a biotechnology company that discovers and engineers allergen-specific antibodies to block and prevent allergic reactions, aiming to treat pediatric and adult patients with severe allergies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.